#TradFi交易分享挑战

Johnson & Johnson's Future Development Outlook

Core conclusion: Johnson & Johnson's stock price is currently at a critical point where "structural recovery" and "systemic risk" coexist

By May 2026, Johnson & Johnson's stock price stabilizes around $225, with a market capitalization of approximately $370 billion. Its valuation logic has shifted from "diversified healthcare giant" to a dual-engine model of "high-growth innovative pharmaceuticals + high-barrier medical technology." Positive factors dominate the long-term trend, but negative risks still have short-term disruptive potential. Over the next 12–18 months, the stock's trajectory will be jointly determined by the pace of breakthroughs in three major pipelines and the final settlement of litigation and settlement processes.

Core positive factors: Explosive innovation pipeline, reshaping growth ceilings

Johnson & Johnson's drug pipeline is rewriting clinical standards at an unprecedented speed. TREMFYA (guselkumab) received FDA approval in April 2026 for ulcerative colitis, becoming the world's first IL-23 inhibitor with dual mechanisms of action. Its impressive efficacy in the QUASAR study: at week 44, clinical remission rate reached 50%, far exceeding the placebo group's 19%; endoscopic remission also reached 34%, more than double the control group. This breakthrough not only consolidates its dominance in the psoriasis field but also propels it onto a new platform for inflammatory disease treatment.

In hematologic oncology, the MajesTEC-3 Phase III data for daratumumab combined with teclistamab (Tec-Dara) shocked the industry: compared to standard therapy, this combination reduced the risk of disease progression or death in relapsed/refractory multiple myeloma patients by 83%. The 36-month progression-free survival rate reached 83.4%, with a 55% reduction in death risk, potentially becoming a new gold standard for second-line treatment, covering over 40% of the global patient population.

In lung cancer treatment, JNJ-6372 (amivantamab, Rybrevant) has been approved in China for first-line treatment of EGFR exon 20 insertion mutant non-small cell lung cancer and has received full approval in the U.S. The PAPILLON study showed that combined chemotherapy reduced disease progression risk by 61%, with median progression-free survival increasing from 7.3 months to 11.5 months. As China’s insurance coverage process accelerates, this drug is expected to achieve explosive growth in the Asian market.

These drugs are no longer just "new drugs," but are redefining the path and expectations of disease treatment.

Core negative factors: Litigation risks unresolved, geopolitical and policy pressures

Despite strong innovation momentum, Johnson & Johnson remains mired in legacy litigation. In May 2026, a Maryland jury awarded $1.56 billion in damages in a talcum powder-related cancer case, setting a record for a single case. To date, the company has paid over $3 billion in settlements, with more than 50,000 unresolved lawsuits pending. If the failure rate continues to rise, it could trigger credit rating downgrades, affecting financing costs and investor confidence.

Meanwhile, geopolitical and policy environments continue to exert pressure. Although a stronger dollar in Q1 2026 brought the company a 1.2% revenue increase and a $0.18 EPS boost, if the dollar continues to appreciate above 110, it will suppress actual demand in Europe and Asia, creating a "exchange rate gains—sales decline" double contradiction. More severely, the Trump administration is planning to impose a 15% tariff on global imported goods; if implemented, it will directly impact Johnson & Johnson’s medical device and pharmaceutical supply chain costs in Europe and Asia.

Additionally, the Inflation Reduction Act (IRA)’s pricing mechanism is systematically compressing pharmaceutical profits. Core drugs like TREMFYA and daratumumab, with annual sales exceeding $1 billion, are now subject to price negotiations. Starting from 2027, these drugs’ prices in the U.S. are expected to be reduced by 25% to 40%, directly eroding gross margins and shrinking future profit margins.

Conclusion: Upside potential lies in "realization" rather than "expectation"

Johnson & Johnson’s future is no longer defined by "safety," but by "innovation."

If the three major core drugs achieve commercial breakthroughs as scheduled—such as TREMFYA surpassing $3 billion in annual sales in UC, Tec-Dara becoming the new standard for second-line treatment globally, and JNJ-6372 capturing over 40% market share in China—its stock price could break through $260, with a market cap heading toward $400 billion.

Conversely, if the talcum powder litigation reaches a settlement exceeding $10 billion by the end of 2026, or IRA pricing causes core drug profits to plummet, the stock could retreat to the $190–$200 range.

Ultimate logic:

You don’t need to buy a "safe" company,

You only need to buy a company that can continue inventing the future even in a storm.

Johnson & Johnson’s stock isn’t betting it won’t have problems,

It’s betting—

That it can invent the future once again.